ArticleScientific reports2025
Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating matrix metalloproteinase profile in early-stage primary biliary cholangitis.Scientific reports · 2026Article
- Lipidome remodeling in primary biliary cholangitis.Lipids in health and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingolipids, key bioactive lipids implicated in inflammation, immune regulation, and fibrosis, are increasingly recognized as contributors to liver pathophysiology. However, their role in primary biliary cholangitis (PBC) remains poorly characterized. In this study, we examined plasma sphingolipid profiles in 45 patients with early-stage PBC receiving ursodeoxycholic acid therapy, comparing them to 30 healthy controls using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS). PBC patients exhibited significantly reduced total sphingolipid levels, notably in phosphorylated species such as sphingosine-1-phosphate (S1P) and sphinganine-1-phosphate (SPA1P). In contrast, C18:1-ceramide was elevated and showed a trend toward association with increased liver stiffness. Very-long-chain ceramides were decreased in the PBC group. Correlation analyses revealed positive associations between sphingolipids and markers of inflammation, including a significant link between sphingosine and interleukin-6. Furthermore, reduced phosphorylated sphingolipids were related to portal hemodynamic changes assessed by Doppler ultrasound. These findings suggest that selective sphingolipid alterations may reflect or contribute to fibrogenesis, immune dysregulation, and portal circulation abnormalities in early PBC, pointing to their potential utility as biomarkers or therapeutic targets in cholestatic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.